Administering immunotherapy to melanoma patients before surgery could shrink tumours and improve quality of life. New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery. Administering… Read More
The US Food and Drug Administration (FDA) has cleared Siren Biotechnology’s first Investigational New Drug (IND) application for its AAV immuno-gene therapy for cancer, enabling the initiation of its first-in-human clinical trial. The IND clearance supports the evaluation of Siren’s lead investigational programme in adult patients with recurrent high-grade glioma. … Read More
AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More
Researchers have made a groundbreaking discovery into why some forms of breast cancer are drug resistant. Cancer scientists at City St George’s, University of London found a ‘molecular signature’ drives drug resistance in an aggressive type of breast cancer known as HER2-positive breast cancer. The… Read More
A new state-of-the-art lab has opened in the UK to accelerate the development of cancer diagnostic solutions. Vortex Biotech has opened a new laboratory at Manchester Science Park, hoping to accelerate the development of cancer diagnostic solutions. The laboratories are designed to GLP-ready specifications, allowing future expansion into clinical trial support and commercial product… Read More
A new study has revealed that low levels of CTDNEP1 may drive early and deadly pancreatic tumours, highlighting its role as a tumour suppressor. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the pancreatic duct. Accounting for… Read More
Corcept Therapeutics has announced that ROSELLA, the company’s Phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival primary endpoint. In ROSELLA, patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a 35% reduction in the risk of… Read More
Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement. Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types. Janux may receive up to $50… Read More
A team of researchers from ChristianaCare and the University of Delaware in the US has uncovered that a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal process, causing immature cells to build up, tissue structure to break down and early tumours to form. … Read More
Oncology biopharmaceutical company Parabilis Medicines has announced the successful closing of a $305 million Series F financing. The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment… Read More
A common gene mutation could be the cause of tumours forming in colorectal cancer patients, a new study suggests. A team of researchers from ChristianaCare and the University of Delaware uncovered how a common genetic mutation in colorectal cancer disrupts the colon’s normal tissue renewal… Read More
A novel DNA-based therapy could increase survival rates for women with platinum-resistant ovarian cancer, a new paper reveals. A new clinical study, published in the International Journal of Gynecological Cancer, shows the DNA-based therapy Elenagen, when administered in combination with standard chemotherapy drug gemcitabine, significantly extended overall survival… Read More
Biotechnology companies STORM Therapeutics and AlidaBio have announced a strategic collaboration to accelerate the development of cancer therapies targeting RNA modifications. STORM will utilise AlidaBio’s EpiPlex and EpiScout next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications, resulting from METTL3 inhibition. Post-transcriptional modification of RNA, including N6-methyladenosine (m6A), adds a crucial layer… Read More
Biopharmaceutical company HUTCHMED has launched the Phase III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a treatment for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). PDAC is a highly aggressive form of cancer, representing over 90% of pancreatic cancer cases. Globally, an estimated 511,000 people were diagnosed… Read More
Breast cancer is the most studied disease globally for a fifth year running, a new report reveals. Phesi’s annual report into the world’s most studied diseases found that breast cancer was the most studied across all subtypes, from triple-negative to PIK3CA. Also in the top five were solid tumours, strokes,… Read More
Biopharmaceuticals company DISCO Pharmaceuticals has entered an exclusive license agreement with biotech company Amgen to advance novel cancer targeted therapies. The companies aim to develop the therapies for a target mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will… Read More
